Related Experiment Video
Updated: Apr 12, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Optimizing Treatment of HER2-Positive Breast Cancer
1Presented by William J. Gradishar, MD, Betsy Bramsen Professor of Breast Oncology, Director of the Maggie Daley Center for Women's Cancer Care at Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Abstract:
The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression--making metastatic disease far less common today--newer treatment advances are also impacting this disease. Dual targeting with pertuzumab and trastuzumab can extend the survival of metastatic disease by more 16 months, but despite such success, resistance to HER2 targeting remains a challenge. Drugs in the pipeline, such as neratinib, may help meet this therapeutic demand. In addition to anti-HER2 agents, chemotherapy is beneficial to patients with tumors 1 cm or larger, but the optimal treatment of smaller tumors is still a work in progress.
Insights
Advances in HER2-positive breast cancer treatment include dual-agent therapy extending survival. However, resistance to HER2 targeting persists, with new drugs like neratinib in development for improved outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- HER2-positive breast cancer treatment has evolved with targeted therapies.
- Adjuvant trastuzumab significantly reduced disease progression.
- Metastatic HER2-positive breast cancer remains a clinical challenge.
Purpose of the Study:
- To review current and emerging treatments for HER2-positive breast cancer.
- To highlight advancements in dual HER2-targeted therapy.
- To address the challenge of resistance to HER2-targeted agents.
Main Methods:
- Literature review of clinical trials and treatment guidelines.
- Analysis of survival data for dual-agent therapies.
- Discussion of novel agents in the treatment pipeline.
Main Results:
- Dual targeting with pertuzumab and trastuzumab improved survival in metastatic disease by over 16 months.
- Resistance to HER2-targeted therapies remains a significant challenge.
- Chemotherapy is effective for tumors ≥1 cm, but optimal treatment for smaller tumors is under investigation.
Conclusions:
- Dual HER2-targeted therapy offers substantial survival benefits.
- Overcoming resistance to HER2-targeted agents is crucial for further progress.
- Ongoing research is needed to optimize treatment strategies, particularly for smaller tumors.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy